Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Basit Öğe Kaydı
dc.authorscopusid56609149600
dc.authorscopusid55504930000
dc.authorscopusid55189913500
dc.authorscopusid57211790367
dc.authorscopusid55402747600
dc.authorscopusid56890954100
dc.authorscopusid6505910645
dc.contributor.authorOruc Z.
dc.contributor.authorKaplan M.A.
dc.contributor.authorGeredeli C.
dc.contributor.authorSari N.Y.
dc.contributor.authorOzaslan E.
dc.contributor.authorAytekin A.
dc.contributor.authorElkiran E.T.
dc.date.accessioned2024-08-04T20:00:47Z
dc.date.available2024-08-04T20:00:47Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as in-depedent prognostic factor for PFS in MBC patients. © 2019 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage1883en_US
dc.identifier.issn1107-0625
dc.identifier.issue5en_US
dc.identifier.pmid31786850en_US
dc.identifier.scopus2-s2.0-85075002263en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1876en_US
dc.identifier.urihttps://hdl.handle.net/11616/91006
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectChemotherapyen_US
dc.subjectEribulinen_US
dc.subjectMetastatic breast canceren_US
dc.subjectPrognostic factorsen_US
dc.titleIs eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu